Table 1.

Clinical and biochemical characteristics of the included clinical trials

Author	Study design	Target Population	Treatment duration	n	Study groups
Boczar et al. 2022 [33]	Prospective randomized trial	HIV infection	6 months	17 18	Rosuvastatin 10 mg/day Control
Emami et al. 2015 [34]	Open-label trial	History of atherosclerosis	3 months	24 24	Atorvastatin 80 mg/day Placebo
Ishii et al. 2010 [42]	Randomized, open-label trial	Adults with stable angina pectoris	6 months	15 15	Atorvastatin 5 mg/day Atorvastatin 20 mg/day
Kim et al. 2020 [35]	Prospective interventional study	Acute coronary syndrome	1 month	13	Atorvastatin 20 mg/day
Lo et al. 2015 [36]	Randomized, double-blind, placebo-controlled	HIV-infected patients	1 year	17 20	Atorvastatin 40 mg/day Placebo
Subramanian et al. 2013 [37]	Randomized, double-blind, active-controlled	Adults with risk factors or with established atherosclerosis	3 months	29 29	Atorvastatin 10 mg/day Atorvastatin 80 mg/day
Tawakol et al. 2013 [38]	Randomized, double-blind trial	Individuals with arterial inflammation	3 months	34 34	Atorvastatin 10 mg/day Atorvastatin 80 mg/day
van der Valk et al. 2016 [41]	Open-label trial	Patients with ankylosing spondylitis	3 months	18	Atorvastatin 40 mg/day
Watanabe et al. 2015 [39]	Randomized, open-label trial	Patients with hyperlipidemia	6 months	10 10	Pitavastatin 2 mg/day Pravastatin 10 mg/day
Wu et al. 2012 [40]	Open-label trial	Patients with atherosclerosis	3 months	43 34	Atorvastatin 40 mg/day Control